MetaCap

Glaukos (GKOS) vs Insulet (PODD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Glaukos (GKOS) has outperformed Insulet (PODD) over the past year, gaining 138.2% versus a loss of 59.8%. Over five years, GKOS leads with a +421.6% price change compared with -54.9% for PODD. Glaukos is the larger company by market cap ($14.05 billion vs $9.24 billion), about 1.5 times the size.

On valuation, Insulet trades at a lower forward P/E (16.8x vs 169.5x for Glaukos). Insulet converts more of its revenue into profit, with a net margin of 9.1% versus -37.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GKOS+138.22%PODD-59.79%
+159%+44%-71%
Nov 21, 20251 yearNov 20, 2026
GKOS+393.27%PODD-55.76%
+434%+177%-80%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GKOS versus PODD key metrics
MetricGKOSPODD
Share price$237.31$133.17
Market cap$14.05B$9.24B
1-day change-0.33%-2.96%
YTD return+110.18%-53.15%
1-year return+138.22%-59.79%
5-year return+421.56%-54.92%
P/E ratio (TTM)—21.76
Forward P/E169.5016.83
EPS (TTM)$-2.95$6.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$507.44M$2.71B
Revenue growth (YoY)+32.33%+30.73%
Net income (latest FY)$-187.69M$247.10M
Gross margin55.72%71.63%
Operating margin-39.33%17.50%
Net margin-36.99%9.12%
52-week high$255.19$342.13
52-week low$93.96$126.40
Distance from 52-week high-7.00%-61.08%
Analyst consensusstrong_buybuy
Avg. price target upside+2.76%+33.60%
Average volume1.19M1.61M
Shares outstanding59.20M69.37M
Employees1,0945,400
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GKOS has outperformed PODD by 198.0 percentage points over the past year.
  • Insulet is more profitable, keeping 9.1 cents of every revenue dollar as net income versus -37.0 cents for Glaukos.

About Glaukos

GKOS stock →

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.

Health Care · Medical/Dental Instruments · 1,094 employees

About Insulet

PODD stock →

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.

Health Care · Medical/Dental Instruments · 5,400 employees

GKOS vs PODD FAQ

Which is bigger, Glaukos or Insulet?

Glaukos (GKOS) is larger, with a market capitalization of $14.05B compared with $9.24B for Insulet (PODD).

Which stock has performed better over the past year, GKOS or PODD?

GKOS returned +138.22% over the past 12 months, compared with -59.79% for PODD (price return, excluding dividends). Past performance does not predict future results.

Are Glaukos and Insulet in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons